Article | November 11, 2020

Advantages In The Continuous Manufacturing Of APIs And Intermediates Under cGMP Conditions

Interview with Dr. Andreas Meudt, Head of Exclusive Synthesis, Evonik

Pharma Article ContipilotplantHanauinterior.jpg

At least seven drug products utilizing continuous manufacturing processes have been approved by the FDA to-date, with many others in clinical development. However, when it comes to APIs and advanced intermediates, there are few pharmaceutical companies that have successfully utilized continuous manufacturing for more than a single process step. In addition, very few have been able to scale-up beyond the kilogram range under cGMP conditions. In this interview with Dr. Andreas Meudt, Head of Exclusive Synthesis for Evonik, the challenges and opportunities for the use of continuous manufacturing for APIs and intermediates are reviewed.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online